Genetic engineering of T cells for adoptive immunotherapy

Angel Varela-Rohena, Carmine Carpenito, Elena E. Perez, Max Richardson, Richard V. Parry, Michael Milone, John Scholler, Xueli Hao, Angela Mexas, Richard G. Carroll, Carl H. June, James L. Riley

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.

Original languageEnglish
Pages (from-to)166-181
Number of pages16
JournalImmunologic Research
Volume42
Issue number1-3
DOIs
StatePublished - Oct 9 2008

Fingerprint

Adoptive Immunotherapy
Genetic Engineering
T-Lymphocytes
T-Cell Antigen Receptor Specificity
CD8 Antigens
Viral Tumor Antigens
Genetic Therapy
HIV Infections
Communicable Diseases
HIV-1
Cell Count
Cell Proliferation
Phenotype
Population
Neoplasms
Therapeutics

Keywords

  • Adoptive T cell therapy
  • CD28
  • Chimeric immunoreceptor
  • Immunotherapy
  • Lentiviral vector
  • NOG mice
  • PD-1
  • TCR
  • Zinc-finger nuclease

ASJC Scopus subject areas

  • Immunology

Cite this

Varela-Rohena, A., Carpenito, C., Perez, E. E., Richardson, M., Parry, R. V., Milone, M., ... Riley, J. L. (2008). Genetic engineering of T cells for adoptive immunotherapy. Immunologic Research, 42(1-3), 166-181. https://doi.org/10.1007/s12026-008-8057-6

Genetic engineering of T cells for adoptive immunotherapy. / Varela-Rohena, Angel; Carpenito, Carmine; Perez, Elena E.; Richardson, Max; Parry, Richard V.; Milone, Michael; Scholler, John; Hao, Xueli; Mexas, Angela; Carroll, Richard G.; June, Carl H.; Riley, James L.

In: Immunologic Research, Vol. 42, No. 1-3, 09.10.2008, p. 166-181.

Research output: Contribution to journalArticle

Varela-Rohena, A, Carpenito, C, Perez, EE, Richardson, M, Parry, RV, Milone, M, Scholler, J, Hao, X, Mexas, A, Carroll, RG, June, CH & Riley, JL 2008, 'Genetic engineering of T cells for adoptive immunotherapy', Immunologic Research, vol. 42, no. 1-3, pp. 166-181. https://doi.org/10.1007/s12026-008-8057-6
Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M et al. Genetic engineering of T cells for adoptive immunotherapy. Immunologic Research. 2008 Oct 9;42(1-3):166-181. https://doi.org/10.1007/s12026-008-8057-6
Varela-Rohena, Angel ; Carpenito, Carmine ; Perez, Elena E. ; Richardson, Max ; Parry, Richard V. ; Milone, Michael ; Scholler, John ; Hao, Xueli ; Mexas, Angela ; Carroll, Richard G. ; June, Carl H. ; Riley, James L. / Genetic engineering of T cells for adoptive immunotherapy. In: Immunologic Research. 2008 ; Vol. 42, No. 1-3. pp. 166-181.
@article{d8bdd333b5b445078aef78e30da87087,
title = "Genetic engineering of T cells for adoptive immunotherapy",
abstract = "To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.",
keywords = "Adoptive T cell therapy, CD28, Chimeric immunoreceptor, Immunotherapy, Lentiviral vector, NOG mice, PD-1, TCR, Zinc-finger nuclease",
author = "Angel Varela-Rohena and Carmine Carpenito and Perez, {Elena E.} and Max Richardson and Parry, {Richard V.} and Michael Milone and John Scholler and Xueli Hao and Angela Mexas and Carroll, {Richard G.} and June, {Carl H.} and Riley, {James L.}",
year = "2008",
month = "10",
day = "9",
doi = "10.1007/s12026-008-8057-6",
language = "English",
volume = "42",
pages = "166--181",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - Genetic engineering of T cells for adoptive immunotherapy

AU - Varela-Rohena, Angel

AU - Carpenito, Carmine

AU - Perez, Elena E.

AU - Richardson, Max

AU - Parry, Richard V.

AU - Milone, Michael

AU - Scholler, John

AU - Hao, Xueli

AU - Mexas, Angela

AU - Carroll, Richard G.

AU - June, Carl H.

AU - Riley, James L.

PY - 2008/10/9

Y1 - 2008/10/9

N2 - To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.

AB - To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.

KW - Adoptive T cell therapy

KW - CD28

KW - Chimeric immunoreceptor

KW - Immunotherapy

KW - Lentiviral vector

KW - NOG mice

KW - PD-1

KW - TCR

KW - Zinc-finger nuclease

UR - http://www.scopus.com/inward/record.url?scp=61849185275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849185275&partnerID=8YFLogxK

U2 - 10.1007/s12026-008-8057-6

DO - 10.1007/s12026-008-8057-6

M3 - Article

C2 - 18841331

AN - SCOPUS:61849185275

VL - 42

SP - 166

EP - 181

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1-3

ER -